AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 832652 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 10
Study 832652 — intervention group
Group type: COMPARATOR
Intervention: Practolol
Number of subjects: 10
Study 31599059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% ketoconazole cream
Number of subjects: 41
Study 31599059 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 41
Study 30204683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting (Group 1)
Number of subjects: 31
Study 30204683 — intervention group
Group type: COMPARATOR
Intervention: Conservative management followed by fat grafting (Group 2)
Number of subjects: 31
Study 27749549 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G (mandibular angle approach)
Number of subjects: 108
Study 27749549 — intervention group
Group type: COMPARATOR
Intervention: Group H (Hartel anterior approach)
Number of subjects: 108
Study 27749549 — intervention group
Group type: EXPERIMENTAL
Intervention: Group G
Number of subjects: 108
Study 27749549 — intervention group
Group type: COMPARATOR
Intervention: Group H
Number of subjects: 108
Study 24424249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 789
Study 24424249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 789
Study 24424249 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 789
Study 24424249 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab PRN (after 6 months of sham treatment)
Number of subjects: 789
Study 24424249 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment followed by ranibizumab 0.5 mg PRN
Number of subjects: 789
Study 22212377 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA 4 g daily for 12 weeks
Number of subjects: 48
Study 22212377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide acetate (LAO) 30 mg via intramuscular injection, given 4-7 days before radiation and on day 22 of treatment.
Number of subjects: 215
Study 20339140 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given 4-7 days before radiation and on day 22 of treatment.
Number of subjects: 215
Study 20339140 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide acetate (LAO)
Number of subjects: 215
Study 20339140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 17592288 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with a composition of 4 Lactobacillus (LAB) and 4 fibers
Number of subjects: 80
Study 17592288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (fibers only)
Number of subjects: 80
Study 17592288 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition supplemented with a composition of 4 LAB and 4 fibers
Number of subjects: 80
Study 16125941 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile polyethylene bearing
Number of subjects: 52
Study 16125941 — intervention group
Group type: COMPARATOR
Intervention: Fixed polyethylene bearing
Number of subjects: 52
Study 15323164 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (at least one course)
Number of subjects: 48
Study 15323164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 48
Study 10525558 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 144
Study 10525558 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol + ipratropium bromide
Number of subjects: 144
Study 10525558 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study 8675251 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8675251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8675251 — intervention group
Group type: EXPERIMENTAL
Intervention: High insulinemia (287 pmol/L)
Number of subjects: 0
Study 8675251 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal conditions
Number of subjects: 0
Study 1999687 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (10 mg daily for 3 months)
Number of subjects: 278
Study 1999687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 1999687 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intake of beta-carotene (diet + medication)
Number of subjects: 278
Study 6095660 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg taken orally at night for 12 months
Number of subjects: 454
Study 6095660 — intervention group
Group type: COMPARATOR
Intervention: cimetidine 400 mg taken orally at night for 12 months
Number of subjects: 454
Study 29766378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% MPC‐polymer mouthwash
Number of subjects: 20
Study 29766378 — intervention group
Group type: COMPARATOR
Intervention: PBS (placebo)
Number of subjects: 20
Study 27686820 — intervention group
Group type: COMPARATOR
Intervention: Acute milk intake
Number of subjects: 28
Study 27686820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic milk intake
Number of subjects: 28
Study 27686820 — intervention group
Group type: COMPARATOR
Intervention: Fruit-juice (control for acute experiment)
Number of subjects: 28
Study 27686820 — intervention group
Group type: COMPARATOR
Intervention: Fruit-juice (control for chronic experiment)
Number of subjects: 28
Study 26362664 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 95
Study 26362664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 23318242 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based Parent Management Training (PMTO, 12 sessions)
Number of subjects: 137
Study 23318242 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 137
Study 21996070 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer kiosk-expedited management
Number of subjects: 624
Study 21996070 — intervention group
Group type: COMPARATOR
Intervention: Usual ED care
Number of subjects: 624
Study 20021458 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programs for asbestos-exposed individuals involving annual pulmonary function tests, chest radiography, and high-resolution computer tomography.
Number of subjects: 0
Study 20021458 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene and protein expression studies aimed at identifying clinically useful biomarkers and new therapeutic targets.
Number of subjects: 0
Study 17511784 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile .04
Number of subjects: 50
Study 17511784 — intervention group
Group type: EXPERIMENTAL
Intervention: GT Rotary
Number of subjects: 50
Study 15338805 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of testosterone, intra-muscularly, every fourth week for 26 weeks
Number of subjects: 29
Study 15338805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12562110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 43
Study 12562110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9613016 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative appraisal condition (safety behaviors employed)
Number of subjects: 82
Study 9613016 — intervention group
Group type: COMPARATOR
Intervention: Positive appraisal condition (safety behaviors not employed)
Number of subjects: 82
Study 8277078 — intervention group
Group type: EXPERIMENTAL
Intervention: SHU 508A (200 mg/ml in 5 ml, 200 mg/ml in 10 ml, 300 mg/ml in 5 ml, 300 mg/ml in 10 ml)
Number of subjects: 35
Study 2551411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (5.4 g eicosapentaenoic acid and 3.6 g docosahexaenoic acid)
Number of subjects: 8
Study 2551411 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil (control)
Number of subjects: 8
Study 786670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensin (average daily dose 84 mg)
Number of subjects: 43
Study 786670 — intervention group
Group type: COMPARATOR
Intervention: Desimipramine (average daily dose 76 mg)
Number of subjects: 43
Study 31599847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 856
Study 31599847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 856
Study 29308523 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g-force
Number of subjects: 156
Study 29308523 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g-force
Number of subjects: 156
Study 29308523 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g-force
Number of subjects: 156
Study 29308523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 26153058 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus intervention (IG)
Number of subjects: 112
Study 26153058 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (CG)
Number of subjects: 112
Study 23668634 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg
Number of subjects: 16
Study 23668634 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 50 mg and 500 mg
Number of subjects: 16
Study 23668634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23668634 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 16
Study 20855554 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave therapy (SWT) - 2500 impulses per session at 0.18 mJ/mm² energy flux density for 4 weeks
Number of subjects: 40
Study 20855554 — intervention group
Group type: COMPARATOR
Intervention: Traditional conservative treatment (TCT) - nonsteroidal anti-inflammatory drugs, physiotherapy, and an exercise program for hamstring muscles for 4 weeks
Number of subjects: 40
Study 19333797 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 68
Study 19333797 — intervention group
Group type: COMPARATOR
Intervention: Control writing
Number of subjects: 68
Study 17766923 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily for 6 months
Number of subjects: 56
Study 17766923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 17766923 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin in obese women
Number of subjects: 56
Study 17766923 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 56
Study 15573333 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual goal setting nursing intervention
Number of subjects: 88
Study 15573333 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-educative nursing interventions
Number of subjects: 88
Study 11137806 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lipid control with simvastatin (group 2)
Number of subjects: 3
Study 11137806 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 3
Study 11137806 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cholesterol <4.7mmol/l (group 3)
Number of subjects: 3
Study 9505749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (5 ml infiltrated along the scrotal incision and 1 ml injected into the vas deferens)
Number of subjects: 42
Study 7881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (oral or intravenous)
Number of subjects: 0
Study 7881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of iron status (serum ferritin and transferrin saturation)
Number of subjects: 0
Study 7881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of hypochromic erythrocytes
Number of subjects: 0
Study 7881986 — intervention group
Group type: EXPERIMENTAL
Intervention: Other methods (erythrocyte ferritin, free erythrocyte protoporphyrin, erythrocyte zinc protoporphyrin levels)
Number of subjects: 0
Study 2119396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkle capsules
Number of subjects: 21
Study 2119396 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablets
Number of subjects: 21
Study 2119396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkle capsules (fasting)
Number of subjects: 21
Study 2119396 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablets (fasting)
Number of subjects: 21
Study 2119396 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkle capsules (nonfasting)
Number of subjects: 21
Study 2119396 — intervention group
Group type: COMPARATOR
Intervention: Food intake
Number of subjects: 21
Study 322267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 600 mg administered as three divided doses with meals for one week.
Number of subjects: 10
Study 322267 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid 3 g administered as three divided doses with meals for one week.
Number of subjects: 10
Study 30770596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-laboratory analysis in Wurzburg
Number of subjects: 43
Study 30770596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-laboratory analysis in Bologna
Number of subjects: 43
Study 30770596 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-laboratory analysis
Number of subjects: 43
Study 28618170 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (four diets varying in macronutrient content)
Number of subjects: 367
Study 24925672 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐trochanteric groove support
Number of subjects: 10
Study 24925672 — intervention group
Group type: COMPARATOR
Intervention: No post‐trochanteric groove support
Number of subjects: 10
Study 23471944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386
Study 23471944 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386
Study 23471944 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal·kg body wt(‐1)·wk(‐1) aerobic training
Number of subjects: 386
Study 23471944 — intervention group
Group type: COMPARATOR
Intervention: All exercise groups
Number of subjects: 386
Study 21690032 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic training with examples from musical instrument category
Number of subjects: 10
Study 21690032 — intervention group
Group type: COMPARATOR
Intervention: Psychological support (Control)
Number of subjects: 10
Study 19786433 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents estimating blood loss
Number of subjects: 227
Study 19786433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses estimating blood loss
Number of subjects: 227
Study 19786433 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctors estimating blood loss
Number of subjects: 227
Study 17559759 — intervention group
Group type: COMPARATOR
Intervention: Chevron osteotomy
Number of subjects: 83
Study 17559759 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 83
Study 15596577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas‐permeable contact lenses (RGPs)
Number of subjects: 116
Study 15596577 — intervention group
Group type: COMPARATOR
Intervention: Soft contact lenses (SCLs)
Number of subjects: 116
Study 15596577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas‐permeable contact lenses (RGPs) and Soft contact lenses (SCLs)
Number of subjects: 116
Study 11152249 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (4 L min(‐1))
Number of subjects: 16
Study 11152249 — intervention group
Group type: COMPARATOR
Intervention: Air (21% oxygen, 4 L min(‐1))
Number of subjects: 16
Study 9091710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine sponge anesthesia
Number of subjects: 150
Study 9091710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine sponge anesthesia with tramadol
Number of subjects: 150
Study 9091710 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (prilocaine/etidocaine mixture)
Number of subjects: 150
Study 9091710 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar injection
Number of subjects: 150
Study 1301126 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation programme (R)
Number of subjects: 205
Study 1301126 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based treatment (H)
Number of subjects: 205
Study 3905773 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 60 mg/day)
Number of subjects: 20
Study 3905773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30372126 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP 4-week maxilla/8-week mandible (n=10)
Number of subjects: 30
Study 30372126 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP 8-week maxilla/12-week mandible (n=10)
Number of subjects: 30
Study 30372126 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP 12-week maxilla/4-week mandible (n=10)
Number of subjects: 30
Study 30372126 — intervention group
Group type: COMPARATOR
Intervention: Control (non-MOP sites)
Number of subjects: 30
Study 30372126 — intervention group
Group type: EXPERIMENTAL
Intervention: MOP (overall)
Number of subjects: 30
Study 30372126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain associated with MOP
Number of subjects: 30
Study 29699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 100,000 u intravenous injection every 8 hours for 7 days
Number of subjects: 123
Study 29699021 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with hyperbaric oxygen and routine medical treatment
Number of subjects: 123
Study 29699021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin treatment
Number of subjects: 123
Study 26873242 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (300,000 IU, IM)
Number of subjects: 95
Study 26873242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 24444545 — intervention group
Group type: EXPERIMENTAL
Intervention: MED on/DBS on
Number of subjects: 18
Study 24444545 — intervention group
Group type: EXPERIMENTAL
Intervention: MED on/DBS off
Number of subjects: 18
Study 24444545 — intervention group
Group type: EXPERIMENTAL
Intervention: MED off/DBS on
Number of subjects: 18
Study 24444545 — intervention group
Group type: COMPARATOR
Intervention: MED off/DBS off
Number of subjects: 18
Study 24444545 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS on
Number of subjects: 18
Study 24444545 — intervention group
Group type: COMPARATOR
Intervention: DBS off
Number of subjects: 18
Study 23183990 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment program
Number of subjects: 800
Study 23183990 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal or written information)
Number of subjects: 800
Study 19237997 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity on Prescription (PAP)
Number of subjects: 101
Study 19237997 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (Control)
Number of subjects: 101
Study 17785618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25 to 75 mg orally 3 times daily)
Number of subjects: 34
Study 17785618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17785618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 34
Study 15932791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg four times a day
Number of subjects: 39
Study 15932791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 11936711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-speciality team intervention
Number of subjects: 157
Study 11936711 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 9616263 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (metabolic alkalosis)
Number of subjects: 8
Study 9616263 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 8
Study 9616263 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl (metabolic acidosis)
Number of subjects: 8
Study 8732147 — intervention group
Group type: EXPERIMENTAL
Intervention: Taponin
Number of subjects: 45
Study 8732147 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 45
Study 2495337 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder message
Number of subjects: 1587
Study 2495337 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter sent to patients
Number of subjects: 1587
Study 2495337 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone call from practice nurse
Number of subjects: 1587
Study 2495337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1587
Study 17557 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (8 mg to 50 mg per day)
Number of subjects: 52
Study 17557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30222051 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited group (household-based prospective cohort study)
Number of subjects: 20000
Study 30222051 — intervention group
Group type: COMPARATOR
Intervention: Uninvited, non-contacted control group
Number of subjects: 20000
Study 30560527 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 45
Study 30560527 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 45
Study 27837709 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) including medication assessment annually between 2004 and 2007
Number of subjects: 1000
Study 27837709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CGA)
Number of subjects: 1000
Study 25602358 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation (intervention group, n = 1225 patients)
Number of subjects: 2449
Study 25602358 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 1224 patients)
Number of subjects: 2449
Study 25602358 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation
Number of subjects: 2449
Study 23376894 — intervention group
Group type: EXPERIMENTAL
Intervention: MiSight contact lenses
Number of subjects: 24